Von Hippel Lindau Disease

Slide 1 · Von Hippel-Lindau disease

A hereditary multisystem tumor-predisposition syndrome

Molecular pathogenesis • CNS morphology • renal and adrenal associations

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Connect germline VHL inactivation to hypoxia-inducible-factor signaling.

Recognize the characteristic cystic and microscopic architecture of hemangioblastoma.

Relate CNS, retinal, renal, adrenal and visceral manifestations to the same syndrome.

Apply lesion morphology and family context in short clinicopathologic cases.

Slide 3 · A multisystem syndrome—not an isolated brain tumor

CNS

Cerebellar and other CNS hemangioblastoma

Retina

Retinal hemangioblastoma

Kidney

Cysts and clear cell RCC

Adrenal

Pheochromocytoma

Viscera

Pancreatic and hepatic cysts

Slide 4 · The phenotype crosses anatomical specialties

Neurosurgical: CNS hemangioblastoma; Ophthalmic: Retinal hemangioblastoma.

Renal: Cysts and clear cell renal cell carcinoma.

Endocrine: Pheochromocytoma; Abdominal: Pancreatic and hepatic cysts.

One organ lesion should prompt consideration of the wider phenotype.

Slide 5 · Population frequency and clinical recognition

A disease frequency of approximately 1 in 30,000–40,000 individuals.

A single lesion does not establish hereditary VHL disease; Assess the constellation of manifestations.

Family history may aid recognition because the predisposition is autosomal dominant.

Symptoms vary with which organ develops a clinically important lesion.

Slide 6 · Autosomal dominant predisposition

A germline pathogenic VHL alteration can be transmitted in an autosomal dominant fashion.

The inherited genotype creates susceptibility to tumor formation in multiple organs.

Subsequent alterations at the cellular level permit individual lesions to emerge.

Familial inheritance and tumor-specific genetic events operate at different levels.

Slide 7 · The organ–lesion matrix

Site

Manifestation

Pathologic category

Cerebellum / CNS

hemangioblastoma

vascular neoplasm.

Retina

hemangioblastoma

vascular neoplasm.

Kidney

cysts / renal cell carcinoma

cystic and malignant epithelial lesions.

Adrenal medulla

pheochromocytoma

catecholamine-producing neuroendocrine tumor.

Pancreas / liver

cysts

visceral non-CNS component.

Slide 8 · VHL is a tumor-suppressor gene

Chromosome 3p25.3

VHL

VHL encodes an element of the ubiquitin ligase machinery.

The gene is a tumor suppressor, rather than a growth-factor gene.

Inactivation deregulates HIF protein turnover.

Slide 9 · The distinction between gene and protein

VHL denotes the gene at 3p25.3; VHL protein acts in the oxygen-response machinery.

The protein acts with other complex members to target defined substrates for degradation.

A loss-of-function mutation affects a cellular control system, not simply an anatomic organ.

Accurate terminology avoids conflating the inherited syndrome with individual tumors.

Slide 10 · Hereditary versus sporadic VHL inactivation

Hereditary disease

Sporadic tumor

Germline VHL predisposition

Acquired VHL alteration in tumor

Multiple organs may be at risk

Localized clonal alteration

Family context matters

Tumor change alone not syndromic proof

Slide 11 · Tumor-suppressor logic in a susceptible cell

Susceptibility

Germline VHL alteration

Cellular event

Additional loss of tumor-suppressor function

Clonal lesion

Tumor emergence in a susceptible tissue

General tumor-suppressor framework; Not a molecular diagnostic criterion

Slide 12 · The normal role of the VHL complex

VHL participates in a ubiquitin ligase that identifies hydroxylated HIF-α for degradation.

Ubiquitin tagging directs the substrate toward proteasomal destruction.

Under adequate oxygen, this pathway restrains unnecessary hypoxia-response signaling.

VHL is therefore a negative regulator of the HIF transcriptional program.

Slide 13 · Oxygen availability determines HIF fate

Normoxia + VHL intact

HIF-α hydroxylation → degradation

Hypoxia + VHL intact

HIF-α stabilization → target genes

Normoxia + VHL absent

HIF-α stabilization → inappropriate signaling

Slide 14 · Normoxia: Controlled HIF degradation

O₂ available

HIF-α hydroxylated

VHL binds HIF-α

Ubiquitination

Proteasomal degradation

Physiologic feedback: Signal is suppressed in normoxia.

Slide 15 · Hypoxia: HIF is stabilized adaptively

Low O₂

Less HIF-α hydroxylation

HIF-α escapes VHL

HIF-α / HIF-β

Target genes induced

Physiologic adaptation: The pathway responds to genuinely low oxygen.

Slide 16 · VHL loss creates “pseudohypoxia”

VHL loss-of-function

HIF-α not removed

HIF nuclear signaling

VEGF and other targets

Vascular / growth effects

Pseudohypoxic signaling: The response persists despite adequate oxygen.

Slide 17 · Three oxygen-response states compared

Normoxia + VHL intact

HIF-α hydroxylation → degradation

Hypoxia + VHL intact

HIF-α stabilization → target genes

Normoxia + VHL absent

HIF-α stabilization → inappropriate signaling

Slide 18 · Prolyl hydroxylation is the oxygen-sensitive step

HIF prolyl hydroxylase requires oxygen to modify HIF-α.

VHL recognition follows this molecular modification rather than detecting O₂ directly.

When hydroxylation fails, HIF-α is no longer efficiently targeted by the VHL complex.

This explains how both hypoxia and VHL loss converge on HIF stabilization.

Slide 19 · Ubiquitination links recognition to destruction

Ubiquitin chains are covalently attached to recognized protein substrates.

The proteasome degrades tagged HIF-α, limiting its nuclear signaling.

Defective VHL uncouples substrate recognition from destruction.

The molecular defect acts upstream of growth-factor production.

Slide 20 · HIF acts in the nucleus as a transcription factor

HIF-α persists

HIF-β partnership

Nuclear transcription

Target gene products

The transcriptional program alters angiogenesis, proliferation and metabolism.

Slide 21 · HIF target genes have different biological outputs

VEGF

Angiogenesis

Erythropoietin

Erythropoiesis

PDGF / IGF-1

Growth signaling

GLUT1 / glycolysis

Metabolic adaptation

Slide 22 · VEGF explains prominent tumor vascularity

VHL pathway disruption increases HIF-driven VEGF expression.

VEGF promotes a dense capillary network and excessive vessel growth.

Hemangioblastomas are exceptionally vascular tumors.

The mechanism provides a direct link between genotype and microscopic architecture.

Slide 23 · Erythropoietin links tumor signaling to blood counts

HIF-dependent erythropoietin expression can increase red-cell production.

Polycythemia in about 10% of patients with hemangioblastoma.

An elevated hematocrit can therefore be paraneoplastic rather than an independent marrow disease.

Polycythemia is possible, not required, for a hemangioblastoma diagnosis.

Slide 24 · Growth signaling contributes alongside angiogenesis

VEGF

Angiogenesis

Erythropoietin

Erythropoiesis

PDGF / IGF-1

Growth signaling

GLUT1 / glycolysis

Metabolic adaptation

Slide 25 · HIF signaling reshapes cellular metabolism

HIF-α stabilization

GLUT1 expression

Glycolytic activity

Growth-favoring metabolism

This is a regulatory mechanism; No fabricated quantitative flux is shown.

Slide 26 · From VHL loss to recognizable morphology

VHL dysfunction → HIF stabilization → VEGF and growth-program expression.

VEGF-related angiogenesis → numerous thin-walled vessels in hemangioblastoma.

Growth and metabolic signaling → support expansion of the neoplastic stromal component.

The microscopic pattern expresses a molecular pathway in tissue form.

Slide 27 · Hemangioblastoma: The characteristic CNS tumor

Hemangioblastoma is a highly vascular neoplasm associated with VHL disease.

It commonly affects the cerebellum and retina but can occur elsewhere within the CNS.

Its tissue architecture combines many vessels with neoplastic stromal cells.

The lesion is not simply a blood-vessel malformation.

Slide 28 · Where hemangioblastomas arise

The cerebellum and retina as common locations.

Other CNS sites can also be involved.

A posterior fossa lesion may produce substantial morbidity through local compression.

Anatomic location matters even when cellular malignancy is not the central issue.

Slide 29 · Gross pattern: A cyst with a mural nodule

Mural nodule

Fluid-filled cyst

Native schematic • not a clinical image

Slide 30 · The mural nodule is the tissue to characterize

Mural nodule

Fluid-filled cyst

Native schematic • not a clinical image

Slide 31 · Microscopy: A capillary-rich neoplasm

Schematic cellular fields

Pink narrow ovals = capillary lumina

Pale larger circles = stromal cells

Not a histology image; Spatial abstraction only

Slide 32 · Stromal cells are the neoplastic component

Schematic cellular fields

Pink narrow ovals = capillary lumina

Pale larger circles = stromal cells

Not a histology image; Spatial abstraction only

Slide 33 · Why hemangioblastoma stromal cells appear vacuolated

The tumor stromal cells contain abundant intracellular lipid.

Lipid-rich cytoplasm produces a characteristic vacuolated or clear appearance.

Clear cytoplasm alone is nonspecific across different tumor types.

Architecture and marker pattern help resolve the differential.

Slide 34 · Inhibin is a useful diagnostic marker

Stromal tumor cells

Inhibin (diagnostically useful)

Stromal tumor cells

VEGF expression

Stromal tumor cells

Erythropoietin expression

Slide 35 · Vessels and stromal cells perform different roles

Schematic cellular fields

Pink narrow ovals = capillary lumina

Pale larger circles = stromal cells

Not a histology image; Spatial abstraction only

Slide 36 · A clinical correlate: Tumor-associated polycythemia

Erythropoietin synthesis by hemangioblastoma stromal cells may increase erythropoiesis.

Polycythemia is observed in a minority, not in all affected patients.

Mechanism: Tumor-derived EPO → bone marrow red-cell production → elevated red-cell mass.

This shows that a CNS tumor can cause systemic hematologic effects.

Slide 37 · Why a low-grade-appearing mass can cause serious harm

Mural nodule

Fluid-filled cyst

Native schematic • not a clinical image

Slide 38 · Retinal hemangioblastoma broadens the phenotype

Retinal vascular lesions are among the common sites described in VHL disease.

Their detection ties an ophthalmic manifestation to a systemic genetic disorder.

Retinal and cerebellar lesions are anatomically different expressions of the same predisposition.

Laser therapy for retinal hemangioblastomas as an organ-directed approach.

Slide 39 · Therapy is directed at clinically significant lesions

Cerebellar hemangioblastoma

Retinal hemangioblastoma

Can produce posterior fossa mass effect

Involves retinal vasculature

Robbins: Resection for symptomatic tumor

Robbins: Laser-directed therapy

Anatomically targeted treatment

Anatomically targeted treatment

Slide 40 · Renal involvement includes cysts and carcinomas

VHL syndrome can produce both renal cysts and renal cell carcinomas.

Cystic disease does not equate automatically with carcinoma.

Renal tumors often arise bilaterally and at multiple sites in hereditary cases.

Renal morphology must distinguish simple cystic involvement from epithelial malignancy.

Slide 41 · The hereditary renal cancer pattern

Hereditary/VHL setting

Typical sporadic setting

Bilateral or multifocal lesions

Often solitary, unilateral

Renal cysts may coexist

No necessary syndromic cystic pattern

Inherited predisposition

Somatic evolution

Slide 42 · Renal cell carcinoma: Gross features

Clear cell RCC often appears as a sharply demarcated, bright yellow-gray-white mass.

Intracellular lipid accumulation contributes to the yellow color.

Hemorrhage and necrosis commonly create heterogeneous cut surfaces.

This gross pattern is for clear cell RCC generally, not uniquely for VHL.

Slide 43 · Renal cell carcinoma: Microscopic growth patterns

Nests of pale cells

Editable architecture schematic

—not a stained specimen

Slide 44 · What makes renal carcinoma cells appear “clear”?

Lipids and glycogen accumulate in the cytoplasm of clear cell RCC cells.

The resulting pale appearance is a biochemical feature, not absence of cytoplasm.

A delicate vascular network often complements this clear-cell architecture.

The appearance differs in context from lipid-rich stromal cells of hemangioblastoma.

Slide 45 · VHL loss is central in sporadic clear cell RCC

Chromosome 3p loss affecting the VHL locus in the great majority of clear cell RCCs.

The second allele may be disrupted by mutation or epigenetic silencing.

Consequent HIF stabilization enhances angiogenesis and growth signals.

Syndromic and sporadic tumors converge mechanistically despite different clinical contexts.

Slide 46 · Clear cell and papillary renal carcinomas differ

Clear cell RCC

Papillary RCC

VHL/3p pathway commonly altered

MET-related pathway in hereditary form

Nests and clear cytoplasm

Papillary/tubulopapillary architecture

Delicate branching vasculature

Papillary cores; Foam cells may occur

Slide 47 · Renal carcinoma may present indirectly

Hematuria may be intermittent or microscopic.

Pain, palpable mass and hematuria together are uncommon as a classic triad.

Some tumors are detected on imaging performed for unrelated reasons.

Systemic symptoms can obscure the renal site of origin.

Slide 48 · Adrenal involvement: Pheochromocytoma

Pheochromocytoma is a neoplasm of adrenal medullary chromaffin cells.

The cells produce catecholamines and may induce paroxysmal or sustained hypertension.

VHL is one of several hereditary syndromes associated with pheochromocytoma.

The endocrine phenotype complements CNS and renal tumor predisposition.

Slide 49 · Pheochromocytoma and the HIF pathway

VHL-associated

MEN2-associated

VHL loss-of-function

RET oncogene activation

Pseudohypoxia / HIF stabilization

Growth-factor receptor pathway

May coexist with RCC/HB

Associated with medullary thyroid cancer

Slide 50 · Pheochromocytoma has a nested architecture

Zellballen nests

Chief-cell groups

Surrounding sustentacular cells

Intervening rich vasculature

Native schematic; Not a micrograph

Slide 51 · Pheochromocytoma: Marker compartmentalization

Chief cells

Chromogranin / synaptophysin

Sustentacular cells

S-100

Architecture

Zellballen nests

Slide 52 · Catecholamine release determines symptoms

Catecholamine excess can cause hypertension and tachycardia.

Paroxysms may include palpitations, headache, sweating and tremor.

Symptoms reflect hormone secretion rather than direct mass effect alone.

A familial syndrome can thus be recognized through an endocrine crisis phenotype.

Slide 53 · The biochemical diagnostic principle

Biochemical evidence

Syndrome evaluation

Plasma or urinary metanephrines

Consider associated organ lesions

Documents catecholamine excess

Inherited context and VHL status

Pheochromocytoma-oriented test

Not a substitute for tumor evaluation

Slide 54 · Visceral cystic lesions are part of the spectrum

VHL-associated cysts may involve the pancreas, liver and kidneys.

Congenital pancreatic cysts in this syndrome.

Cysts coexist with neoplastic manifestations but are not equivalent to malignancy.

A multiorgan cystic pattern can be a clue when interpreted with characteristic tumors.

Slide 55 · Cyst and neoplasm are different categories

Cystic hemangioblastoma

Visceral organ cyst

Solid vascular mural nodule

May be a non-neoplastic cyst

Cerebellum / CNS

Kidney, pancreas, liver

Associated with a neoplasm

Must be classified by site and lining

Slide 56 · A pattern-based approach to possible VHL disease

Characteristic lesion

Other organs

Familial context

Syndrome assessment

Slide 57 · Genotype–phenotype interpretation requires care

Hereditary disease

Sporadic tumor

Germline VHL predisposition

Acquired VHL alteration in tumor

Multiple organs may be at risk

Localized clonal alteration

Family context matters

Tumor change alone not syndromic proof

Slide 58 · Case 1: Cystic posterior fossa mass

A patient presents with a cerebellar cystic lesion containing a small solid mural nodule.

Histology shows prominent thin-walled capillaries and lipid-rich vacuolated stromal cells.

Question: What is the most likely lesion, and what wider phenotype deserves consideration?

Slide 59 · Case 1: Morphology identifies the lesion

The cyst-plus-mural-nodule pattern and vascular stromal-cell histology support hemangioblastoma.

Consider VHL disease when this tumor is placed in a broader patient or family context.

Additional concern: Retinal lesions, renal neoplasia, pheochromocytoma and visceral cysts.

Do not diagnose inherited VHL solely from one morphologically typical tumor.

Slide 60 · Case 2: Multiple renal masses

A patient has bilateral renal masses and several renal cysts.

A resected mass shows clear polygonal cells arranged in nests with delicate vessels.

Question: Which carcinoma subtype fits, and what syndrome-level association is relevant?

Slide 61 · Case 2: Apply renal and genetic morphology

Clear cytoplasm, nested growth and thin branching vessels support clear cell RCC.

Bilateral multifocal tumors with renal cysts raise suspicion for hereditary predisposition including VHL.

The same VHL pathway also occurs in sporadic clear cell RCC.

Molecular alteration in a renal tumor and inherited syndrome diagnosis are not interchangeable.

Slide 62 · Case 3: Endocrine lesion in multisystem disease

A patient with a family history of VHL disease develops episodic hypertension and palpitations.

An adrenal medullary tumor shows zellballen nests of chromaffin cells.

Question: Identify the tumor and explain how it fits the VHL phenotype.

Slide 63 · Case 3: Distinguish the endocrine component

The adrenal lesion is a pheochromocytoma; Catecholamine production explains symptoms.

VHL loss may favor HIF stabilization and pseudohypoxic biology.

Evaluate the lesion in the context of other VHL-associated manifestations.

It is a distinct neoplasm from hemangioblastoma despite the shared syndrome.

Slide 64 · Integrated pathology synthesis

VHL inactivation

HIF accumulation

VEGF / EPO / metabolism

Hemangioblastoma and other tumors

From inherited predisposition to gene regulation, tissue morphology and multisystem clinical disease.

Slide 65 · Four diagnostic distinctions worth retaining

VHL syndrome ≠ any sporadic tumor with a VHL mutation.

Hemangioblastoma stromal cell ≠ the endothelial lining of its capillaries.

Cystic hemangioblastoma ≠ pancreatic or renal congenital cyst.

Inhibin in hemangioblastoma ≠ the neuroendocrine marker profile of pheochromocytoma.

Slide 66 · Summary: Mechanism, morphology, phenotype

Molecular: VHL tumor-suppressor dysfunction stabilizes HIF under inappropriate oxygen conditions.

CNS: Hemangioblastoma often forms a mural nodule and cyst, with capillaries plus vacuolated stromal cells.

Systemic: Renal clear cell carcinoma, pheochromocytoma and pancreatic/hepatic/renal cysts are important associations.

Clinical reasoning: Integrate family context, organ distribution and lesion-specific morphology.

Slide 67 · Source material and image limitations

PRIMARY TEXTBOOK

Robbins, Cotran & Kumar: Pathologic Basis of Disease

CORE SOURCE

Chapter 28: Von Hippel-Lindau Disease

RELATED SOURCE SECTIONS

Chapter 7: VHL–HIF signaling • Chapter 20: Renal cell carcinoma • Chapter 24: Pheochromocytoma